Tranche

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Retrieved on: 
Tuesday, January 16, 2024
Euronext, Finance, UCART123, Form, Tranche, Commercial code, EIB, Form 6-K, Exercise, BofA Securities, European Investment Bank, Security (finance)

Tranche B is expected to be disbursed by the EIB by January 25, 2024.

Key Points: 
  • Tranche B is expected to be disbursed by the EIB by January 25, 2024.
  • The Company plans to use the proceeds of Tranche B towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, and UCART123.
  • The total number of shares issuable upon exercise of the Tranche B Warrants represents circa 2% of the Company’s outstanding share capital as at their issuance date.
  • Tranche B will mature six years from its disbursement date and will accrue interest at a rate of 7% per annum capitalized annually and payable at maturity.

Sierra Space Awarded $740M Prime Contract by Space Development Agency

Retrieved on: 
Tuesday, January 16, 2024
Defense, Technology, Satellite, Aerospace, Manufacturing, Contracts, Employment, Department of Defence, Multimedia, Sierra Nevada Corporation, OTA, Tranche, Investment, Safety, SDA, Orbit, Space Development Agency, Arms industry

Sierra Space , a leading commercial space company building the first end-to-end business and technology platform in space, announced today that it has won a significant contract award by the Space Development Agency (SDA) for 18 missile warning and tracking satellites.

Key Points: 
  • Sierra Space , a leading commercial space company building the first end-to-end business and technology platform in space, announced today that it has won a significant contract award by the Space Development Agency (SDA) for 18 missile warning and tracking satellites.
  • View the full release here: https://www.businesswire.com/news/home/20240116346883/en/
    Sierra Space, a leading commercial space company building the first end-to-end business and technology platform in space, announced on January 16, 2024, that it has won a significant contract award by the Space Development Agency (SDA) for 18 missile warning and tracking satellites.
  • “Under the $740 million SDA contract, Sierra Space will deliver an 18-satellite constellation for missile detection and warning with fire control quality tracks,” said Sierra Space CEO Tom Vice.
  • The company will develop, integrate and test its space vehicles at Sierra Space's satellite production facilities in Colorado.

Rocket Lab Makes its Defense Prime Debut with $0.5 Billion Contract to Design and Build Satellite Constellation for Space Development Agency

Retrieved on: 
Monday, January 8, 2024
Internet, Contracts, Data Management, Technology, White House, Federal Government, Defense, Satellite, Government Technology, Air, Transport, Aerospace, Public Policy, Government, Manufacturing, Lab, Rocket, Acquisition, Space Development Agency, LEO, Rocket Lab, SDA, Radio, Webcast, Intelligence, Tranche, Communications satellite

The contract establishes Rocket Lab’s position as a leading satellite prime contractor, providing supply chain diversity to the Department of Defense (DoD) through vertical integration.

Key Points: 
  • The contract establishes Rocket Lab’s position as a leading satellite prime contractor, providing supply chain diversity to the Department of Defense (DoD) through vertical integration.
  • The SDA is procuring satellites in two-year "tranches" to build out a proliferated constellation in LEO to deliver needed space-based capabilities to the joint war fighter.
  • “This contract marks the beginning of Rocket Lab’s new era as a leading satellite prime.
  • Rocket Lab satellite technology and components have been integrated into more than 1,700 satellite missions globally.

Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise

Retrieved on: 
Thursday, December 28, 2023
Sale, Form, Act, Loan agreement, CNS, Patient, Central nervous system, The Act, Tranche, Exercise, Security (finance)

The shares of common stock issued upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No.

Key Points: 
  • The shares of common stock issued upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No.
  • 333-251006), filed with the U.S. Securities Exchange (“SEC”) on November 27, 2020 and declared effective on December 4, 2020.
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offerings.
  • The aggregate gross proceeds to the Company from the offerings were approximately $4 million, before deducting placement agent fees and other offering expenses.

Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise

Retrieved on: 
Wednesday, December 27, 2023
Regulation D, Sale, Form, Act, Loan agreement, Trevena Inc, CNS, Patient, Central nervous system, The Act, Tranche, Exercise, Security (finance)

The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No.

Key Points: 
  • The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No.
  • 333-251006), filed with the U.S. Securities Exchange (“SEC”) on November 27, 2020 and declared effective on December 4, 2020.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.
  • The aggregate gross proceeds to the Company from the offerings are expected to be approximately $4 million, before deducting placement agent fees and other offering expenses.

Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank

Retrieved on: 
Friday, December 22, 2023
Investment, EUR, European Investment Bank, BofA Securities, European, Tranche, EIB, Obesity, Fine chemical

20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it has entered into a finance agreement for a loan facility of EUR 90 million from the European Investment Bank ("EIB"), the long-term lending institution of the European Union owned by its Member States.

Key Points: 
  • 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it has entered into a finance agreement for a loan facility of EUR 90 million from the European Investment Bank ("EIB"), the long-term lending institution of the European Union owned by its Member States.
  • "We are very pleased with the endorsement and support from the EIB for our investments in our R&D pipeline," said Henriette Wennicke, Chief Financial Officer of Zealand Pharma.
  • The loan facility may be utilized in up to three tranches of EUR 50 million (Tranche A), EUR 20 million (Tranche B) and EUR 20 million (Tranche C), respectively, with disbursement of each tranche subject to pre-specified milestones being met.
  • The conditions for disbursement of the first tranche (Tranche A) have been met and the EUR 50 million is expected to be available to Zealand in the beginning of 2024.

Red Pine Announces C$5.0 Million “Bought Deal” Private Placement of Tranche 1 Flow-Through Shares and Tranche 2 Flow-Through Shares

Retrieved on: 
Thursday, November 16, 2023
Sale, Special-purpose acquisition company, TSX Venture Exchange, OTCQB, Income Tax Act 1967, RPX, Initial public offering, Tranche, Income Tax Act, Offering, Security (finance)

TORONTO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) ("Red Pine" or the “Company”) is pleased to announce that it has entered into an agreement with Haywood Securities Inc. (“Haywood”), as lead underwriter and sole bookrunner, on its own behalf and on behalf of a syndicate of underwriters (together with Haywood, the “Underwriters”) pursuant to which the Underwriters have agreed to purchase, on a "bought deal" private placement basis, (i) 18,182,000 tranche 1 flow-through shares (the “Tranche 1 FT Shares”) of the Company at a price of C$0.22 per Tranche 1 FT Share (the “Tranche 1 FT Issue Price”), and (ii) 3,704,000 tranche 2 flow-through shares (the “Tranche 2 FT Shares” and together with the Tranche 1 FT Shares, the “Offered FT Shares”) of the Company at a price of C$0.27 per Tranche 2 FT Share (the “Tranche 2 FT Issue Price”), for gross proceeds to the Company of up to C$5,000,120 (the “Offering”).

Key Points: 
  • All Qualifying Expenditures will be renounced in favour of the subscribers of the Offered FT Shares effective December 31, 2023.
  • The Offering is being made by way of private placement in Canada.
  • The securities issued under the Offering will be subject to a hold period in Canada expiring four months and one day from the closing date of the Offering.
  • The Offering is subject to final acceptance of the TSXV.

IDEX Biometrics ASA - Contemplated Private Placement

Retrieved on: 
Wednesday, November 15, 2023
Private placement, EGM, IDEX Biometrics, Bookrunner, NOT, Oslo Stock Exchange, Convertible bond, Limited company, Security (finance), VPS, Risk, ANY, History, NOK, CET, External reference pricing, OTC Bulletin Board, EUR, Prospectus, FOR, File, Reference, Acquisition, Tranche, ISIN, ASA, Regulation, Private, VWAP, Interest, Bank, Cryptocurrency

IDEX Biometrics ASA (the "Company"), a leading provider of advanced fingerprint identification and authentications solutions, has retained Arctic Securities AS as sole manager and bookrunner (the "Manager") to advise on and effect a private placement (the "Private Placement") of new shares in the Company (the "Offer Shares") to raise gross proceeds of up to NOK 35 million.

Key Points: 
  • IDEX Biometrics ASA (the "Company"), a leading provider of advanced fingerprint identification and authentications solutions, has retained Arctic Securities AS as sole manager and bookrunner (the "Manager") to advise on and effect a private placement (the "Private Placement") of new shares in the Company (the "Offer Shares") to raise gross proceeds of up to NOK 35 million.
  • With such cost reductions and the combined proceeds from the contemplated Private Placement and Convertible Bond, the Company expects to be fully funded through 2024.
  • The subscription price per Offer Share in the Private Placement (the "Offer Price") and the number of Offer Shares to be issued in the Private Placement will be determined by the board of directors of the Company (the "Board") following an accelerated bookbuilding process.
  • A private placement enables the Company to raise capital in an efficient manner, and the Private Placement is structured to ensure that a market-based subscription price is achieved.

Terran Orbital Reports Record Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Satellite, Defense, Contracts, Robotics, Technology, Aerospace, Government Technology, Manufacturing, EBITDA, NYSE, Rivada Networks, PIPE, Entrepreneurship, Orbital Corporation, Investment, Adjusted gross income, EAC, Depreciation, Public expenditure, Transport layer, Marketing, Uncertainty, Capital, Capital expenditure, Automation, GAAP, Human, Hand, Tranche, Growth, Video game

Terran Orbital Corporation (NYSE: LLAP) ("Terran Orbital" or the "Company"), a leading manufacturer of satellite products primarily serving the aerospace and defense industries, today announced financial results and operational highlights for the three and nine months ended September 30, 2023.

Key Points: 
  • Terran Orbital Corporation (NYSE: LLAP) ("Terran Orbital" or the "Company"), a leading manufacturer of satellite products primarily serving the aerospace and defense industries, today announced financial results and operational highlights for the three and nine months ended September 30, 2023.
  • Cost of sales for the third quarter of 2023 was $34.2 million compared to $27.8 million in the same quarter in 2022.
  • Gross profit was $9.7 million in the third quarter of 2023, compared to $37 thousand in the same quarter in 2022.
  • Adjusted EBITDA(1) was $(13.0) million for the third quarter of 2023, compared to $(13.9) million in the same quarter of 2022.

Momentus Inc. Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Mobile, Wireless, Other Defense, Technology, Defense, Other Manufacturing, Other Transport, Satellite, Engineering, Air, Transport, Aerospace, Telecommunications, Manufacturing, Webcast, ID, Internet of things, SDA, RIDE, Exercise, Traction, C3S, Vigoride, Orbit, SatRevolution, Aarhus University, Small business, SpaceX, Space Development Agency, MET, Water, Tranche, Small Business Innovation Research, AVS, Inc., California Institute of Technology, Microwave electrothermal thruster, Space, Rendezvous, Communications satellite, Aarhus, Seagate Technology

Momentus Inc. (NASDAQ: MNTS) (“Momentus” or the “Company”), a U.S. commercial space company that offers satellite buses, transportation, and other in-space infrastructure services, today announced its financial results for the third quarter of 2023.

Key Points: 
  • Momentus Inc. (NASDAQ: MNTS) (“Momentus” or the “Company”), a U.S. commercial space company that offers satellite buses, transportation, and other in-space infrastructure services, today announced its financial results for the third quarter of 2023.
  • "In the third quarter, we saw significant traction in the commercial market that continues into the fourth quarter.
  • Momentus placed a satellite in Low Earth Orbit for Aarhus on the Vigoride-6 mission that launched in April 2023.
  • Momentus will host a conference call to discuss the results today, November 14, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).